Sklar Kirsh LLP is a GOLD SPONSOR at the Centurion One Capital 6th Annual LA Summit
Los Angeles, California--(Newsfile Corp. - May 28, 2025) - SKLAR KIRSH LLP is pleased to announce it is a GOLD SPONSOR at the Centurion One Capital 6th Annual LA Summit held at the iconic Beverly Hills Hotel from Monday, June 2nd to Thursday, June 5th , 2025, in Los Angeles, California.
This four-day invitation only and curated event will feature:
public and private companies across emerging and growth sectors
highly selective audience of global growth investors
insightful panel discussions led by globally renowned experts and thought leaders
VIP networking events and a captivating entertainment program
Centurion One Capital 6th Annual LA Summit
Format: Presentations, Panel Discussions and 1 X 1 Investor MeetingsPresentation Dates: Wednesday, June 4th and Thursday, June 5th, 2025Time: 9:00 AM PDT - 5:00 PM PDT Venue: The Beverly Hills Hotel
For more information and registration details, please visit: https://www.centuriononecapital.com/la-summit.
Sklar Kirsh LLP is looking forward to attending this landmark event and having the opportunity to engage with industry leaders and global growth investors and building meaningful relationships and exploring the next wave of growth companies shaping North America's future.
About Sklar Kirsh LLP
Sklar Kirsh LLP is a corporate, real estate, and litigation law firm founded by attorneys from nationally and internationally recognized firms who provide top tier legal services in an entrepreneurial, sophisticated, and focused manner. We counsel privately held and public companies, family offices, and high net-worth individuals on legal and business matters that arise at all stages of the business and real estate life cycles, including mergers and acquisitions, purchase and sale agreements, equity and debt financings, leasing, corporate governance, tax, executive compensation and employment arrangements, and dispute resolution. We also provide premiere level litigation representation to individuals and businesses in a variety of market sectors with deep experience in handling business and real estate litigation.
Learn more about Sklar Kirsh LLP at www.sklarkirsh.com.
Andrew Kirsh3108456416akirsh@sklarkirsh.comJeff Sklarjsklar@sklarkirsh.com
About Centurion One Capital
Centurion One Capital ("Centurion One") is the premier independent Investment Banking firm dedicated to fueling the growth and success of growth companies in North America. With an unwavering commitment to delivering comprehensive financial solutions and strategic guidance, Centurion One is a trusted strategic partner and catalyst to propel issuers to unlock their full potential.
Our team comprises seasoned professionals who combine extensive financial expertise with deep knowledge of various sectors. We take a proactive and results-driven approach, working closely with our clients to develop tailored strategies and execute transactions that maximize value and drive long-term success.
Centurion One - Empowering Growth. Driving Innovation. Partnering for Success.
For more information about Centurion One, visit www.centuriononecapital.com.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253756
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043. The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information. Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection. WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol-free formulation of Ameluz® nanoemulsion gel in the US Food and Drug Administration's (FDA's) publication 'Approved Drug Products with Therapeutic Equivalence Evaluations' (commonly known as the Orange Book). The Orange Book is a key reference for healthcare providers, pharmacists, and payers and is the definitive source for identifying FDA-approved drug products. Inclusion of a drug in the Orange Book confirms that the FDA recognizes that the drug meets their rigorous standards for safety, efficacy, and quality. In addition, patents listed confer intellectual property protections which may include the drug's composition, formulation, or specific uses. Listing of the patent for the propylene glycol-free formulation of Ameluz® prevents generic competition as long as the patent is valid, which currently is December 2043. The revised formulation, which eliminates propylene glycol—a well-known allergen for some patients1—demonstrates Biofrontera's continued commitment to innovation and patient-centric development. It offers a significant improvement for individuals who are sensitive to this excipient without compromising the treatment's effectiveness. The patent for the revised formulation of Ameluz® was issued on April 22, 2025, and lasts until December 8, 2043. The formulation itself was accepted by the FDA and has been in use since 2024. 'We are proud to announce the inclusion of the patent for our propylene glycol-free formula in the Orange Book,' said Dr Hermann Luebbert, CEO and Chairman of Biofrontera Inc. 'This recognition validates the differentiated profile of our propylene glycol-free formulation, offering physicians and patients a formulation that reduces the potential for allergic reactions while maintaining the efficacy of Ameluz® RhodoLED PDT.' References: Jacob SE, et al. 'Contact Allergy to Propylene Glycol: A Review.' Dermatitis. 2008;19(3):157–163. About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on LinkedIn and Twitter. Forward-Looking Statements Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company's expectations; the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company's filings with the Securities and Exchange Commission (the 'SEC'), which can be obtained on the SEC's website at Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact:Investor RelationsAndrew Barwicki1-516-662-9461ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
Meet With iQor CXBPO™ at Customer Contact Week Las Vegas 2025
Industry Experts to Showcase infinityAiQ™ Platform and Next-Gen VOC Analytics FT. LAUDERDALE, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Leaders from iQor CXBPO™, an award-winning customer experience business process outsourcing (BPO) solutions provider unifying AI, analytics, and human expertise, will exhibit at Customer Contact Week (CCW) Las Vegas 2025 at Caesars Forum from June 10 to 12. As the world's largest customer contact event, CCW provides a premier platform for CX leaders to explore cutting-edge innovations and strategic insights shaping the future of customer service. Attendees are invited to connect with iQor's CX experts to learn how global brands are leveraging the company's operational excellence, AI-enabled solutions, and next-generation VOC analytics to drive efficiency, reduce costs, and elevate customer satisfaction. iQor will highlight the power of its infinityAiQ™ platform, the engine that powers its revolutionary CXBPO™ model, turning every customer interaction into business intelligence and every CX process into a growth opportunity — unifying people, processes, and insights to deliver value like never before. Backed by a global team of 180+ data scientists, analysts, and Ph.D.s., iQor's integration of AI and analytics combines proprietary tools, enriched datasets, and advanced partner technologies for exceptional CX. iQor will also demonstrate the benefits of its collaboration with OpenAI. iQor is the first CXBPO to integrate OpenAI's advanced language models into its proprietary analytics platform, empowering brands to instantly analyze customer sentiment and behavior across millions of interactions. This real-time intelligence enables personalized experiences, proactive issue resolution, and smarter decision-making throughout the customer journey. Stop by Booth 1624 in the Expo Hall between 8 a.m. and 5 p.m. PDT on Tuesday, June 10; between 8 a.m. and 6 p.m. PDT on Wednesday, June 11; and between 8 a.m. and 5:30 p.m. PDT on Thursday, June 12, to explore how AI-driven solutions can transform your customer experience strategy. To book time with an iQor CX leader, visit the iQor CCW Las Vegas 2025 event page. To learn more about CCW Las Vegas 2025, visit the official event website. About iQor CXBPO™iQor CXBPO™ is a trusted partner in intelligent customer experience solutions, delivering exceptional results for global brands. With 40,000 employees across 10 countries, we combine 30 years of industry expertise with cutting-edge AI-driven innovations to optimize customer interactions at every stage. Our agile, scalable solutions ensure seamless omnichannel engagement, driving loyalty and measurable business success. Recognized as a Great Place to Work® and a leader in CX excellence, we elevate performance through a people-first approach, operational expertise, and secure, technology-enabled solutions. Learn more at CONTACT: Contact Nicole Gobbo Director of Communications
Yahoo
01-06-2025
- Yahoo
UCLA facing WCWS elimination after comeback sputters in loss to Texas Tech
UCLA starting pitcher Taylor Tinsley, shown here delivering against UC Santa Barbara on May 16, gave up four hits and three earned runs in a 3-1 loss to Texas Tech at the Women's College World Series on Saturday. (Kyusung Gong / Associated Press) UCLA had its chances against a familiar foe at the Women's College World Series on Saturday. But the Bruins, who walked off with a win against Oregon late early Friday morning, failed to duplicate the same magic against Texas Tech's NiJaree Canady. Advertisement Canady, the hard-throwing former Stanford ace, pitched a complete game seven-hitter with seven strikeouts and two walks to help secure a 3-1 win for the Red Raiders and a spot in Monday's semifinals. Read more: More Bruin magic: Jessica Clements' walk-off homer lifts UCLA past Oregon at WCWS The Bruins left five runners on base against Canady — three in the second inning and two more in the seventh. Back-to-back singles by Alexis Ramirez and Rylee Slimp to lead off the seventh gave UCLA hope against Canady. But Bragg popped out to second, pinch-hitter Sofia Mujica struck out and Slimp was tagged out to end the game. The Bruins (55-12) now must travel a different path if they are going to challenge for a 13th national title. UCLA plays Tennessee on Sunday at noon (PDT) and must win to extend their season. Advertisement Texas Tech (52-12) needs just one win to reach the championship series. The Red Raiders will face either four-time defending champion Oklahoma or Oregon, who play Sunday. Taylor Tinsley (15-5) pitched a complete game four-hitter with one walk and two strikeouts for UCLA, which scored on a solo home run by Kaniya Bragg in the fifth to make it 1-1. Get the best, most interesting and strangest stories of the day from the L.A. sports scene and beyond from our newsletter The Sports Report. This story originally appeared in Los Angeles Times.
